CLASS II Drug recall · Reported 3 Jul 2024 · FDA Enforcement Report

Duloxetine Delayed-Release Capsules, USP, 30mg recalled

Golden State Medical Supply is recalling Duloxetine Delayed-Release Capsules, USP, 30mg, distributed nationwide in the US. The recall was initiated on 13 May 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025
Quantity recalled21,655 (30 count bottle), 34,149 (90 count bottle)

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0568-2024
FDA event ID
94639
Recalling firm
Golden State Medical Supply, Camarillo, CA
Classification
Class II
Status
Terminated
Recall initiated
13 May 2024
FDA classified
25 Jun 2024
Reported
3 Jul 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antidepressants

Timeline

13 May 2024Recall initiated by company
25 Jun 2024Classified by FDA+43 days
3 Jul 2024Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.

Where it was distributed

Nationwide in the U.S.

Nationwide

Questions about this recall

Is Duloxetine Delayed-Release Capsules, USP, 30mg recalled?

Yes. Golden State Medical Supply recalled Duloxetine Delayed-Release Capsules, USP, 30mg on 13 May 2024. The recall is Class II and its status is Terminated. Recall number D-0568-2024.

Why was it recalled?

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Which lots are affected?

Lot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025

Where was it sold?

Nationwide in the U.S.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Golden State Medical Supply

All 55

Other Duloxetine recalls

All 55